Dr. Paolo Lombardi
Owner, Naxospharma; Co-owner & CSO, AESIS Therapeutics
-
links
Owner, Naxospharma; Co-owner & CSO, AESIS Therapeutics
-
- links
- email.........p.lombardi@naxospharma.eu
- https://scholar.google.com/citations?user=LK22z00AAAAJ&hl=en
Phone - +39-0238203181 (Work)
Address Naxospharma srl via G. Di Vittorio, 70 20026 Novate Milanese Italy
Summary
Professional with extensive experience in the Pharmaceutical Industry. Presently, scientist-entrepreneur.
• Backgrounds in organic synthetic chemistry, process research chemistry, medicinal chemistry.
• Demonstrated expertise in the drug discovery in important therapeutic fields by successful leadership of many result-oriented research projects.
• Creativity and strong commitment to the invention and IP protection of several therapeutical New Chemical Entities, some of which have been advanced into clinical development and into global market.
• Capacity in planning the preclinical iter of candidate compounds, from the design of viable syntheses for the scale-up process up to their earlier therapeutic evaluations. Insight into IND development processes.
• Basically a self-starter, self-motivated drug hunter with a ‘can-do’ spirit and a sense for focusing on creating the drug, very comfortable in operating in start-up situations, securing skills in managing and motivating research staff and facilitating relationships with the scientific community, with the vision and creativity to ‘make things happen’.
• Co-inventor and Inventor of 65+ patents, author and co-author of 150+ research papers, reviews, abstracts, invited lectures and seminars. Teaching appointments at Universities, Master courses & Specialist Schools
https://scholar.google.it/citations?user=LK22z00AAAAJ&hl=en
Specialties: My( his ) statements:
• Knowing about innovation is one thing; making it work is another.
• Chemistry-driven drug discovery may be politically incorrect, but it works.
• Life sciences which neglect chemistry should arouse our suspicion.
• Cells follow the laws of chemistry
• We wish to cooperate with those who have both knowledge and integrity
• Nature does not care what politicians call it, she just keeps on doing it
.
• Backgrounds in organic synthetic chemistry, process research chemistry, medicinal chemistry.
• Demonstrated expertise in the drug discovery in important therapeutic fields by successful leadership of many result-oriented research projects.
• Creativity and strong commitment to the invention and IP protection of several therapeutical New Chemical Entities, some of which have been advanced into clinical development and into global market.
• Capacity in planning the preclinical iter of candidate compounds, from the design of viable syntheses for the scale-up process up to their earlier therapeutic evaluations. Insight into IND development processes.
• Basically a self-starter, self-motivated drug hunter with a ‘can-do’ spirit and a sense for focusing on creating the drug, very comfortable in operating in start-up situations, securing skills in managing and motivating research staff and facilitating relationships with the scientific community, with the vision and creativity to ‘make things happen’.
• Co-inventor and Inventor of 65+ patents, author and co-author of 150+ research papers, reviews, abstracts, invited lectures and seminars. Teaching appointments at Universities, Master courses & Specialist Schools
https://scholar.google.it/citations?user=LK22z00AAAAJ&hl=en
Specialties: My( his ) statements:
• Knowing about innovation is one thing; making it work is another.
• Chemistry-driven drug discovery may be politically incorrect, but it works.
• Life sciences which neglect chemistry should arouse our suspicion.
• Cells follow the laws of chemistry
• We wish to cooperate with those who have both knowledge and integrity
• Nature does not care what politicians call it, she just keeps on doing it
.
Experience
Co-founder & CSO
AESIS Therapeutics
A dual spin out company from Naxospharma (Milan, Italy) and Aromics (Barcelona, Spain) aiming at moving inventive findings from the two parent companies into early stage clinical development. Current projects: new agents against HER2+ breast cancer and against malignant mesotheliomas.
President and Owner
Naxospharma srl
Chemistry-driven, R&D-only small pharma/biotech aiming at finding new drug candidates to license-out for further development.
Incorporates the culture, know how elements and the people most strongly related to the major achievements of late Farmitalia: distamycin (Herperal ®); daunomycin (Daunoblastin®): doxorubicin (Adriblastin®, Adriamycin®); epirubicin (Farmorubicin®, Ellence®); idarubicin (Zavedos®); exemestane (Aromasin®).
Grants from European Commission, Italian Ministries, Regional and local authorities. Recipient of Premio Mercurio d'Oro (Golden Mercury Award) 2010, Regione Lombardia.
Recipient of Premio Internazionale (International Prize) Le Fonti as the best Research & Biotech Company http://www.premiolefonti.it/vincitori.php
Creation of 5 patents portfolio.
Board:
Paolo Lombardi, PhD - President, owner
Prof. Federico-Maria Arcamone - Member
Caterina Vallani, DVM – Member, co-owner
Corporate coworkers and scientists on Linkedin:
Franco Buzzetti
Gaetano Fiorillo
Tanjia Monir Syeda
Cristina Geroni
Carlo Battistini
Laura Franchini
Incorporates the culture, know how elements and the people most strongly related to the major achievements of late Farmitalia: distamycin (Herperal ®); daunomycin (Daunoblastin®): doxorubicin (Adriblastin®, Adriamycin®); epirubicin (Farmorubicin®, Ellence®); idarubicin (Zavedos®); exemestane (Aromasin®).
Grants from European Commission, Italian Ministries, Regional and local authorities. Recipient of Premio Mercurio d'Oro (Golden Mercury Award) 2010, Regione Lombardia.
Recipient of Premio Internazionale (International Prize) Le Fonti as the best Research & Biotech Company http://www.premiolefonti.it/vincitori.php
Creation of 5 patents portfolio.
Board:
Paolo Lombardi, PhD - President, owner
Prof. Federico-Maria Arcamone - Member
Caterina Vallani, DVM – Member, co-owner
Corporate coworkers and scientists on Linkedin:
Franco Buzzetti
Gaetano Fiorillo
Tanjia Monir Syeda
Cristina Geroni
Carlo Battistini
Laura Franchini
Head of Medicinal Chemistry
Chrysalon
Lyon area
Partecipating in creating value for this biotech since its foundation.
Partecipating in creating value for this biotech since its foundation.
Consultant
IBI G. Lorenzini
Rome area
Advise and counsel in the definition of new targets and new “state of the art” technologies for suitable research programmes. Building network of external collaborators. Starting-up projects.
Advise and counsel in the definition of new targets and new “state of the art” technologies for suitable research programmes. Building network of external collaborators. Starting-up projects.
Vice-President for Chemistry
Menarini Ricerche S.p.A.
Rome area
Building and development of a chemistry-driven competitive Drug Discovery Department. Discovery chemistry (design and synthesis of DNA-interacting compounds, receptor antagonists, enzyme inhibitors), Structural chemistry (high resolution NMR and MS, molecular modelling), Technology chemistry (solid phase continuous flow synthesis, peptides, libraries). Direction of projects and programmes to discover anticancer and antiviral agents, neurokinin antagonists, antiprotozoarian agents, aromatase inhibitors. Establishing efficiency and success rate of delivering drug candidates. Discovered NCEs which entered pre- and clinical development (Sabarubicin, 3rd generation antitumour anthracycline).
Creation of 18 patents corporate portfolio.
Building and development of a chemistry-driven competitive Drug Discovery Department. Discovery chemistry (design and synthesis of DNA-interacting compounds, receptor antagonists, enzyme inhibitors), Structural chemistry (high resolution NMR and MS, molecular modelling), Technology chemistry (solid phase continuous flow synthesis, peptides, libraries). Direction of projects and programmes to discover anticancer and antiviral agents, neurokinin antagonists, antiprotozoarian agents, aromatase inhibitors. Establishing efficiency and success rate of delivering drug candidates. Discovered NCEs which entered pre- and clinical development (Sabarubicin, 3rd generation antitumour anthracycline).
Creation of 18 patents corporate portfolio.
Project leader
Farmitalia Carlo Erba
Milan area
Antinfective research: contributions to the chemistry and synthesis of non-classical β-lactams: penems, nocardicin and clavulanic acid analogues
Process research chemistry: studies of viable syntheses of β-lactams, anthracyclines and their intermediates
Anticancer research: to discover inhibitors of aromatase (ultimate enzyme in oestrogens biosynthesis) as potential drugs for the treatment of breast and other hormone-dependent tumours. Achieved the goal of discovering Exemestane (marketed as AROMASIN) and the clinical follow-up Minamestane, both orally active for post-menopausal breast cancer therapy. Provided viable industrial synthetic methods for both compounds,
Creation of 34 patents corporate portfolio.
Antinfective research: contributions to the chemistry and synthesis of non-classical β-lactams: penems, nocardicin and clavulanic acid analogues
Process research chemistry: studies of viable syntheses of β-lactams, anthracyclines and their intermediates
Anticancer research: to discover inhibitors of aromatase (ultimate enzyme in oestrogens biosynthesis) as potential drugs for the treatment of breast and other hormone-dependent tumours. Achieved the goal of discovering Exemestane (marketed as AROMASIN) and the clinical follow-up Minamestane, both orally active for post-menopausal breast cancer therapy. Provided viable industrial synthetic methods for both compounds,
Creation of 34 patents corporate portfolio.
Research assistant
Southampton University Chemistry Department
Research work on catalysed Diels-Alder cycloaddition for the syntheses of industrially useful compounds in the laboratory of late Prof. R. C. Cookson (Research grant presented by Firmenich et Cie., Geneve, CH).
2nd Lieutenant Naval Weapons
Italian Navy
Reserve officer of the civil service. Ammunition factory at Aulla. Warship “C. Duilio”.
Education
University of Southampton
PhD, Chemistry
Dissertation in synthetic organic chemistry. Supervisor: Prof. R. C. Cookson
Italian Naval Academy at Livorno
Midshipman, Naval Weapons
Drilling period (4 months) en route to become a Navy officer of the civil service
Università degli Studi di Milano
doctor, Chemistry
Dissertation in the chemistry of natural products
| 6-Methylenandrosta-1, 4-diene-3, 17-dione (FCE 24304): a new irreversible aromatase inhibitor
D Giudici, G Ornati, G Briatico, F Buzzetti, P Lombardi, E Di Salle
Journal of steroid biochemistry 30 (1), 391-394
| 131 | 1988 |
| New developments in antitumor anthracyclines
F Arcamone, F Animati, G Capranico, P Lombardi, G Pratesi, S Manzini, ...
Pharmacology & therapeutics 76 (1), 117-124
| 95 | 1997 |
| Synthesis of aryl 2-benzofuranyl and aryl 2-indolyl carbinols of high enantiomeric purity via palladium-catalyzed heteroannulation of chiral arylpropargylic alcohols
M Botta, V Summa, F Corelli, G Di Pietro, P Lombardi
Tetrahedron: Asymmetry 7 (5), 1263-1266
| 93 | 1996 |
| Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo
F Arcamone, F Animati, M Berettoni, M Bigioni, G Capranico, AM Casazza, ...
Journal of the National Cancer Institute 89 (16), 1217-1223
| 71 | 1997 |
| Berberine: new perspectives for old remedies
M Tillhon, LMG Ortiz, P Lombardi, AI Scovassi
Biochemical pharmacology 84 (10), 1260-1267
| 68 | 2012 |
| A rapid, safe and convenient procedure for the preparation and use of diazomethane
P Lombardi
Chemistry and industry
| 54 | 1990 |
| 4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione
E Di Salle, D Giudici, G Ornati, G Briatico, R D'alessio, V Villa, P Lombardi
The Journal of steroid biochemistry and molecular biology 37 (3), 369-374
| 43 | 1990 |
| Large scale preparation of enantiopure S-ketoprofen by biocatalysed kinetic resolution
N D’Antona, P Lombardi, G Nicolosi, G Salvo
Process Biochemistry 38 (3), 373-377
| 39 | 2002 |
| Substituted 1-[(benzofuran-2-yl)-phenylmethyl]-imidazoles as potent inhibitors of aromatase in vitro and in female rats in vivo
R Whomsley, E Fernandez, PJ Nicholls, HJ Smith, P Lombardi, ...
The Journal of steroid biochemistry and molecular biology 44 (4), 675-676
| 39 | 1993 |
| Exemestane, a new steroidal aromatase inhibitor of clinical relevance
P Lombardi
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2), 326-337
| 37 | 2002 |
| A new irreversible aromatase inhibitor, 6-methylenandrosta-1, 4-diene-3, 17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors
T Zaccheo, D Giudici, P Lombardi, E Di Salle
Cancer chemotherapy and pharmacology 23 (1), 47-50
| 37 | 1989 |
| New anthracycline disaccharides. Synthesis of L-daunosaminyl-α (1→ 4)-2-deoxy-L-rhamnosyl and of L-daunosaminyl-α (1→ 4)-2-deoxy-L-fucosyl daunorubicin analogues
F Animati, F Arcamone, M Berettoni, A Cipollone, M Franciotti, P Lombardi
J. Chem. Soc., Perkin Trans. 1, 1327-1329
| 29 | 1996 |
| 6-substituted androsta-1, 4-diene-3, 17-diones
F Buzzetti, N Barbugian, P Lombardi, EDI Salle
US Patent 4,808,616
| 25 | 1989 |
| Biophysical studies on the effect of the 13 position substitution of the anticancer alkaloid berberine on its DNA binding
D Bhowmik, M Hossain, F Buzzetti, R D’Auria, P Lombardi, GS Kumar
The Journal of Physical Chemistry B 116 (7), 2314-2324
| 22 | 2012 |
| 4-amino androstendione derivatives and process for their preparation
F Faustini, R d'Alessio, V Villa, EDI Salle, P Lombardi
US Patent 4,757,061
| 22 | 1988 |
| Binding of Epstein-Barr virus nuclear antigen 1 to DNA: inhibition by distamycin and two novel distamycin analogues
G Feriotto, A Ciucci, C Mischiati, F Animati, P Lombardi, P Giacomini, ...
European Journal of Pharmacology: Molecular Pharmacology 267 (2), 143-149
| 21 | 1994 |
| Synthesis of Two Distamycin Analogs and Their Binding Mode to d (CGCAAATTTGCG) 2 in the 2: 1 Solution Complexes as Determined by Two-Dimensional 1H-NMR
F Animati, FM Arcamone, MR Conte, P Felicetti, A Galeone, P Lombardi, ...
Journal of medicinal chemistry 38 (7), 1140-1149
| 20 | 1995 |
| Killing of tumor cells: a drama in two acts
V Giansanti, M Tillhon, G Mazzini, E Prosperi, P Lombardi, AI Scovassi
Biochemical pharmacology 82 (10), 1304-1310
| 17 | 2011 |
| Antimalarial activity of synthetic analogues of distamycin
P Lombardi, A Crisanti
Pharmacology & therapeutics 76 (1), 125-133
| 16 | 1997 |
| Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, ...
Molecular pharmacology 50 (3), 603-609
| 16 | 1996 |
https://scholar.google.com/citations?user=LK22z00AAAAJ&hl=en&cstart=20&pagesize=20
- Naxospharma SRL
- Chemistry Lab
- Address: Via Giuseppe di Vittorio, Novate Milanese, ItalyPhone: +39 02 3820 2846
AESIS
..........
/////////
No comments:
Post a Comment